Clinical Trials · NCT03322631
A Study of Tirzepatide (LY3298176) in Japanese Participants With Type 2 Diabetes
- Phase
- Phase 1
- Recruitment status
- Completed
- Sponsor
- Eli Lilly and Company
- Enrollment
- 48
- Start date
- Nov 2017
- Locations
- 2 sites, Japan
- Primary endpoint
- Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration